Maravai Lifesciences Holdings Inc (NASDAQ:MRVI) — Market Cap & Net Worth
Market Cap & Net Worth: Maravai Lifesciences Holdings Inc (MRVI)
Maravai Lifesciences Holdings Inc (NASDAQ:MRVI) has a market capitalization of $540.93 Million ($540.93 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12115 globally and #2858 in its home market, demonstrating a 8.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Maravai Lifesciences Holdings Inc's stock price $3.73 by its total outstanding shares 145022751 (145.02 Million). Analyse how efficiently does Maravai Lifesciences Holdings Inc generate cash to see how efficiently the company converts income to cash.
Maravai Lifesciences Holdings Inc Market Cap History: 2020 to 2026
Maravai Lifesciences Holdings Inc's market capitalization history from 2020 to 2026. Data shows change from $4.07 Billion to $540.93 Million (-31.74% CAGR).
Index Memberships
Maravai Lifesciences Holdings Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #313 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1154 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.03% | #178 of 263 |
Weight: Maravai Lifesciences Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Maravai Lifesciences Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Maravai Lifesciences Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.05x
Maravai Lifesciences Holdings Inc's market cap is 3.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.07 Billion | $284.10 Million | $76.89 Million | 14.32x | 52.91x |
| 2021 | $6.08 Billion | $799.24 Million | $182.04 Million | 7.60x | 33.38x |
| 2022 | $2.08 Billion | $883.00 Million | $220.21 Million | 2.35x | 9.42x |
| 2023 | $949.90 Million | $288.94 Million | -$119.03 Million | 3.29x | N/A |
| 2024 | $790.37 Million | $259.19 Million | -$144.85 Million | 3.05x | N/A |
Competitor Companies of MRVI by Market Capitalization
Companies near Maravai Lifesciences Holdings Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Maravai Lifesciences Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Maravai Lifesciences Holdings Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Maravai Lifesciences Holdings Inc's market cap moved from $4.07 Billion to $ 540.93 Million, with a yearly change of -31.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $540.93 Million | +14.77% |
| 2025 | $471.32 Million | -40.37% |
| 2024 | $790.37 Million | -16.79% |
| 2023 | $949.90 Million | -54.23% |
| 2022 | $2.08 Billion | -65.85% |
| 2021 | $6.08 Billion | +49.38% |
| 2020 | $4.07 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Maravai Lifesciences Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $540.93 Million USD |
| MoneyControl | $540.93 Million USD |
| MarketWatch | $540.93 Million USD |
| marketcap.company | $540.93 Million USD |
| Reuters | $540.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Producti… Read more